NASDAQ:BIIBBiogen Stock Price, Forecast & News

$306.72

+7.07 (+2.36 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$298.12

Now: $306.72▼

$308.27

50-Day Range

$292.25

MA: $310.11▼

$342.55

52-Week Range

$215.77

Now: $306.72▼

$374.99

Volume1.29 million shs

Average Volume1.15 million shs

Market Capitalization$50.05 billion

P/E Ratio9.47

Dividend YieldN/A

Beta0.54

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Beat the Market (BTM) Rank^™

2.1 Analyst's Opinion

Consensus Rating
Biogen has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 11 buy ratings, 14 hold ratings, and 5 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $317.46, Biogen has a potential upside of 3.5% from its current price of $306.72.
Amount of Analyst Coverage
Biogen has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0 Community Rank

Outperform Votes
Biogen has received 1,596 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Biogen has received 1,038 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Biogen has received 60.59% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote “Outperform” if you believe BIIB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Biogen does not currently pay a dividend.
Dividend Growth
Biogen does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biogen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $718,565.00 in company stock.
Percentage Held by Insiders
Only 0.54% of the stock of Biogen is held by insiders.
Percentage Held by Institutions
87.45% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5 Earnings and Valuation

Earnings Growth
Earnings for Biogen are expected to decrease by -1.24% in the coming year, from $33.13 to $32.72 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biogen is 9.47, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 16.21.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biogen is 9.47, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.49.
Price to Earnings Growth Ratio
Biogen has a PEG Ratio of 0.65. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Biogen has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.72 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:BIIB

Previous Symbol

CUSIP09062X10

CIK875045

Webwww.biogen.com

Phone617-679-2000

Debt

Debt-to-Equity Ratio0.39

Current Ratio1.73

Quick Ratio1.54

Price-To-Earnings

Trailing P/E Ratio9.47

Forward P/E Ratio9.26

P/E Growth0.65

Sales & Book Value

Annual Sales$14.38 billion

Price / Sales3.48

Cash Flow$39.53 per share

Price / Cash Flow7.76

Book Value$73.93 per share

Price / Book4.15

Profitability

EPS (Most Recent Fiscal Year)$33.57

Net Income$5.89 billion

Net Margins40.76%

Return on Equity49.22%

Return on Assets24.26%

Miscellaneous

Employees7,400

Outstanding Shares163,190,000

Market Cap$50.05 billion

Next Earnings Date7/28/2020 (Estimated)

OptionableOptionable

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.

Biogen (NASDAQ:BIIB) Frequently Asked Questions

How has Biogen's stock been impacted by COVID-19 (Coronavirus)?

Biogen's stock was trading at $294.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BIIB stock has increased by 4.2% and is now trading at $306.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Biogen?

30 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 sell ratings, 14 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Biogen.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Biogen.

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) issued its quarterly earnings data on Wednesday, April, 22nd. The biotechnology company reported $9.14 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $7.73 by $1.41. The biotechnology company had revenue of $3.53 billion for the quarter, compared to the consensus estimate of $3.41 billion. Biogen had a net margin of 40.76% and a return on equity of 49.22%. The company's quarterly revenue was up 1.3% on a year-over-year basis. During the same quarter last year, the business earned $6.98 EPS. View Biogen's earnings history.

How will Biogen's stock buyback program work?

Biogen declared that its board has initiated a stock buyback plan on Monday, December 23rd 2019, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's management believes its stock is undervalued.

What price target have analysts set for BIIB?

30 brokers have issued 1 year price objectives for Biogen's stock. Their forecasts range from $235.00 to $410.00. On average, they expect Biogen's share price to reach $317.46 in the next year. This suggests a possible upside of 3.5% from the stock's current price. View analysts' price targets for Biogen.

Has Biogen been receiving favorable news coverage?

News coverage about BIIB stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biogen earned a coverage optimism score of -1.5 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutBiogen.

Are investors shorting Biogen?

Biogen saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,170,000 shares, an increase of 9.4% from the April 30th total of 3,810,000 shares. Based on an average daily volume of 2,080,000 shares, the days-to-cover ratio is presently 2.0 days. Currently, 2.6% of the shares of the company are sold short. View Biogen's Current Options Chain.

Who are some of Biogen's key competitors?

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Walt Disney (DIS), Celgene (CELG), Micron Technology (MU) and Intel (INTC).

Who are Biogen's key executives?

Biogen's management team includes the following people:

Mr. Michel Vounatsos, CEO & Director (Age 57)
Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 54)
Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 62)
Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 50)
Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 53)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.83%), Primecap Management Co. CA (9.78%), State Street Corp (5.06%), Clearbridge Investments LLC (2.70%), Wellington Management Group LLP (2.51%) and Geode Capital Management LLC (2.07%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin. View institutional ownership trends for Biogen.

Which institutional investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Clearbridge Investments LLC, Wellington Management Group LLP, AQR Capital Management LLC, Assenagon Asset Management S.A., Fort Washington Investment Advisors Inc. OH, Nuveen Asset Management LLC, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin. View insider buying and selling activity for Biogen.

Which institutional investors are buying Biogen stock?

BIIB stock was acquired by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, APG Asset Management N.V., Orbimed Advisors LLC, BlackRock Inc., Bank of New York Mellon Corp, Rock Springs Capital Management LP, Redmile Group LLC, and Ardevora Asset Management LLP. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos. View insider buying and selling activity for Biogen.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $306.72.

How big of a company is Biogen?

Biogen has a market capitalization of $50.05 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff